Pushing Boundaries

DEBBIE HART | PRESIDENT & CEO, BIONJ

What is quite astonishing is the fact that people now live on average 10 years longer than they did in 1989, and the global pharmaceutical industry invested $200 billion in R&D in 2020, which is an unprecedented amount.

PAMELA FRALICK | PRESIDENT, INNOVATIVE MEDICINES CANADA (IMC)

Canada is a nation of settlers, along with our Indigenous populations. As a result, we’re able to conduct clinical trials on a broad, diverse population, especially in larger cities like Montreal, Toronto, and Vancouver, which is extremely attractive for the innovative pharmaceutical industry.

KEREN HARUVI SNIR | PRESIDENT, SANDOZ U.S.

According to our studies, by 2025, 1.2 million additional patients could get access to biologics just by virtue of the fact that we will have a greater volume of biosimilars available.

JOE PANETTA | PRESIDENT & CEO, BIOCOM CALIFORNIA

We believe opportunity exists for collaboration between California-based companies and other markets. Biocom California has an office in Tokyo, and we plan to support our members who wish to expand to Asia and Europe.

RENE RUSSO | CEO, XILIO THERAPEUTICS

We believe that cancer treatment can be revolutionized through medicine that effectively tricks tumors into activating their own treatment, while protecting the patient's healthy tissue, organs, and cells.